Elvitegravir: HIV Drug, Mechanism & Use
Elvitegravir is an antiretroviral medication used to treat HIV-1 infection. It belongs to the class of integrase inhibitors and is always used as part of combination therapy.
Things worth knowing about "Elvitegravir"
Elvitegravir is an antiretroviral medication used to treat HIV-1 infection. It belongs to the class of integrase inhibitors and is always used as part of combination therapy.
What is Elvitegravir?
Elvitegravir (abbreviated: EVG) is an antiretroviral drug belonging to the class of integrase strand transfer inhibitors (INSTIs). It is used in the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and in pediatric patients above a certain body weight. Elvitegravir is not marketed as a standalone drug; it is exclusively available in fixed-dose combination products together with other antiretroviral agents.
Indication
Elvitegravir is indicated for the treatment of HIV-1 infection as part of antiretroviral combination therapy (ART). It is a component of several approved fixed-dose combinations, including:
- Stribild®: Elvitegravir + Cobicistat + Emtricitabine + Tenofovir Disoproxil Fumarate
- Genvoya®: Elvitegravir + Cobicistat + Emtricitabine + Tenofovir Alafenamide
These combinations allow for a complete antiretroviral regimen in a single tablet taken once daily, significantly improving patient adherence to therapy.
Mechanism of Action
HIV requires the enzyme integrase to insert its viral DNA into the genetic material of the human host cell. Elvitegravir selectively inhibits this process by blocking the strand transfer reaction of the integrase enzyme. As a result, viral DNA cannot be integrated into the human genome, viral replication is interrupted, and the viral load in the blood decreases. Because elvitegravir is rapidly metabolized in the body, it is always co-administered with the pharmacokinetic booster cobicistat, which slows the breakdown of elvitegravir and ensures adequate plasma levels throughout the day.
Dosage and Administration
Elvitegravir is administered in the form of the above-mentioned fixed-dose combination tablets, taken orally once daily. The tablet should always be taken with food, as food significantly improves the absorption of the drug. The precise dosage depends on the specific combination product and the individual condition of the patient. Special caution is required in patients with reduced kidney function, as some of the co-administered agents can affect renal function.
Side Effects
Elvitegravir is generally well tolerated. The most commonly reported side effects associated with its combination products include:
- Nausea and diarrhea
- Headache
- Fatigue and dizziness
- Elevated serum creatinine levels (caused by the booster cobicistat, without true impairment of kidney function)
- Changes in blood lipid levels
Rarer but more serious adverse effects can include lactic acidosis (a build-up of lactic acid in the blood) or hepatic steatosis (fatty liver), particularly when tenofovir disoproxil fumarate is used as a co-component.
Drug Interactions
Because elvitegravir is co-administered with the CYP3A4 inhibitor cobicistat, there are numerous potential drug interactions. Cobicistat inhibits several hepatic enzymes (primarily CYP3A4), which affects the metabolism of many other medications. Patients should always inform their doctor or pharmacist about all medications, supplements, and herbal products they are taking. Certain drugs (e.g., rifampicin, St. John's Wort, some antiepileptics) are contraindicated, as they can significantly reduce the efficacy of elvitegravir.
Therapeutic Context
Elvitegravir-containing regimens are considered effective and well tolerated for treatment-naive patients as well as for certain treatment-experienced patients without relevant resistance mutations. The once-daily single-tablet regimen promotes adherence, which is critical for long-term treatment success. Regular monitoring (viral load, CD4 cell count, renal function) is essential throughout the course of therapy.
References
- European Medicines Agency (EMA): Genvoya - Summary of Product Characteristics. Available at: www.ema.europa.eu
- European Medicines Agency (EMA): Stribild - Summary of Product Characteristics. Available at: www.ema.europa.eu
- EACS European AIDS Clinical Society: Guidelines Version 12.0, 2023. Available at: www.eacsociety.org
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryVasectomized
Carbon dioxide
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Elvitegravir